Spark Therapeutics Inc. (ONCE) Trading 2.1% Higher
Spark Therapeutics Inc. (NASDAQ:ONCE)’s share price traded up 2.1% during trading on Friday . The company traded as high as $55.70 and last traded at $54.40, with a volume of 159,993 shares changing hands. The stock had previously closed at $53.28.
Several equities analysts have recently issued reports on ONCE shares. Zacks Investment Research cut Spark Therapeutics from a “buy” rating to a “hold” rating in a research note on Tuesday, August 16th. Cantor Fitzgerald reiterated a “buy” rating and issued a $94.00 price objective on shares of Spark Therapeutics in a research note on Thursday, August 11th. Wedbush reiterated an “underperform” rating and issued a $29.00 price objective (up previously from $28.00) on shares of Spark Therapeutics in a research note on Wednesday, August 10th. Jefferies Group reiterated a “hold” rating on shares of Spark Therapeutics in a research note on Friday, August 5th. Finally, Chardan Capital set a $35.00 price objective on Spark Therapeutics and gave the company a “hold” rating in a research note on Thursday, July 21st. Two investment analysts have rated the stock with a sell rating, five have given a hold rating and seven have given a buy rating to the stock. The stock has an average rating of “Hold” and an average target price of $61.20.
The stock’s market cap is $1.68 billion. The company has a 50-day moving average of $56.67 and a 200-day moving average of $43.65.
Spark Therapeutics (NASDAQ:ONCE) last announced its quarterly earnings results on Wednesday, August 10th. The company reported ($1.04) EPS for the quarter, missing the Thomson Reuters’ consensus estimate of ($0.97) by $0.07. During the same period in the previous year, the company earned ($0.60) EPS. The business earned $1.29 million during the quarter, compared to the consensus estimate of $1.17 million. Spark Therapeutics’s revenue was up .0% compared to the same quarter last year. On average, equities research analysts expect that Spark Therapeutics Inc. will post ($3.94) EPS for the current year.
In other Spark Therapeutics news, Director Anand Mehra sold 500 shares of the company’s stock in a transaction dated Tuesday, May 31st. The stock was sold at an average price of $60.00, for a total transaction of $30,000.00. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through this link. Also, major shareholder Hospital Of Philade Children’s sold 1,000,000 shares of the company’s stock in a transaction dated Monday, June 20th. The stock was sold at an average price of $42.30, for a total value of $42,300,000.00. Following the sale, the insider now owns 6,768,707 shares of the company’s stock, valued at $286,316,306.10. The disclosure for this sale can be found here.
A hedge fund recently raised its stake in Spark Therapeutics stock. Schwab Charles Investment Management Inc. boosted its stake in Spark Therapeutics Inc. (NASDAQ:ONCE) by 3.9% during the fourth quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The fund owned 34,539 shares of the company’s stock after buying an additional 1,283 shares during the period. Schwab Charles Investment Management Inc. owned approximately 0.14% of Spark Therapeutics worth $1,565,000 as of its most recent SEC filing.
Spark Therapeutics, Inc (Spark) is engaged in developing products in the field of gene therapy. The Company focuses on treating orphan diseases. It has a pipeline of product candidates targeting multiple rare blinding conditions, hematologic disorders and neurodegenerative diseases. Its SPK-RPE65 (voretigene neparvovec) targets genetic blinding conditions known as inherited retinal dystrophies (IRDs).
Get Analysts' Upgrades and Downgrades Daily - Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.